CA3196946A1 - Fused heteroaryl compounds and their use as camkii inhibitors - Google Patents

Fused heteroaryl compounds and their use as camkii inhibitors

Info

Publication number
CA3196946A1
CA3196946A1 CA3196946A CA3196946A CA3196946A1 CA 3196946 A1 CA3196946 A1 CA 3196946A1 CA 3196946 A CA3196946 A CA 3196946A CA 3196946 A CA3196946 A CA 3196946A CA 3196946 A1 CA3196946 A1 CA 3196946A1
Authority
CA
Canada
Prior art keywords
group
optionally substituted
alkyl
compound
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3196946A
Other languages
English (en)
French (fr)
Inventor
Nobuyuki Matsunaga
Junya Shirai
Tomohiro Okawa
Yasufumi Miyamoto
Zenyu Shiokawa
Takashi Nakahata
Akito SHIBUYA
Akira Kawada
Malcolm Maccoss
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cardurion Pharmaceuticals Inc
Original Assignee
Cardurion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardurion Pharmaceuticals Inc filed Critical Cardurion Pharmaceuticals Inc
Publication of CA3196946A1 publication Critical patent/CA3196946A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CA3196946A 2020-09-28 2021-09-24 Fused heteroaryl compounds and their use as camkii inhibitors Pending CA3196946A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063084217P 2020-09-28 2020-09-28
US63/084,217 2020-09-28
PCT/US2021/052025 WO2022067082A1 (en) 2020-09-28 2021-09-24 Fused heteroaryl compounds and their use as camkii inhibitors

Publications (1)

Publication Number Publication Date
CA3196946A1 true CA3196946A1 (en) 2022-03-31

Family

ID=80821052

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3196946A Pending CA3196946A1 (en) 2020-09-28 2021-09-24 Fused heteroaryl compounds and their use as camkii inhibitors

Country Status (14)

Country Link
US (2) US11795172B2 (enExample)
EP (1) EP4216948A4 (enExample)
JP (1) JP7824282B2 (enExample)
KR (1) KR20230107551A (enExample)
CN (1) CN116940354A (enExample)
AU (1) AU2021350015A1 (enExample)
CA (1) CA3196946A1 (enExample)
CL (1) CL2023000894A1 (enExample)
CO (1) CO2023005189A2 (enExample)
IL (1) IL301480A (enExample)
MX (1) MX2023003610A (enExample)
PE (1) PE20240148A1 (enExample)
TW (1) TW202229273A (enExample)
WO (1) WO2022067082A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7824282B2 (ja) * 2020-09-28 2026-03-04 カーデュリオン・ファーマシューティカルズ・インコーポレイテッド 縮合ヘテロアリール化合物およびＣａＭＫＩＩ阻害剤としてのその使用
WO2023134692A1 (zh) * 2022-01-13 2023-07-20 浙江同源康医药股份有限公司 多环类化合物及其用途
CN115160235B (zh) * 2022-08-10 2023-12-15 宜宾学院 一种2,3-二氢喹唑啉-4(1h)-酮类化合物及其超声合成方法
US20250145630A1 (en) * 2023-11-07 2025-05-08 Cardurion Pharmaceuticals, Inc. Polymorphs of a pyridinylimidazo[1,2-b]pyridazine

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1317266A2 (en) 2000-08-08 2003-06-11 Ortho-McNeil Pharmaceutical, Inc. Neuroprotective 2-pyridinamine compositions and related methods
HK1054393B (en) 2000-09-20 2009-08-28 Ortho-Mcneil Pharmaceutical, Inc. Pyrazine derivatives as modulators of tyrosine kinases
US20030187026A1 (en) * 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
JP2007504229A (ja) 2003-09-02 2007-03-01 メルク　エンド　カムパニー　インコーポレーテッド 代謝調節型グルタミン酸受容体−５のモジュレーターとしてのビピリジルアミン類およびエーテル類
US7776857B2 (en) 2007-04-05 2010-08-17 Amgen Inc. Aurora kinase modulators and method of use
US9216173B2 (en) 2011-10-05 2015-12-22 Merck Sharp & Dohme Corp. 2-Pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors
HRP20180037T1 (hr) 2012-04-17 2018-03-23 Fujifilm Corporation Heterociklični spoj koji sadrži dušik ili njegovu sol
CA2894126A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors and uses thereof
CN107074856A (zh) * 2014-09-05 2017-08-18 阿略斯泰罗斯医疗公司 CaMKII抑制剂及其用途
AR110252A1 (es) 2016-11-30 2019-03-13 Gilead Sciences Inc Compuestos heterocíclicos fusionados como inhibidores de la quinasa cam
CN110799190B (zh) 2017-03-27 2024-04-19 卡都瑞恩医药有限公司 杂环化合物
JP7447098B2 (ja) 2018-09-25 2024-03-11 カーデュリオン・ファーマシューティカルズ・インコーポレイテッド アミノピリミジン化合物
WO2020068846A1 (en) * 2018-09-25 2020-04-02 Heterocyclic Compound Heterocyclic compound
US20230000842A1 (en) 2019-01-17 2023-01-05 Samumed, Llc Methods of treating cartilage disorders through inhibition of clk and dyrk
JP7824282B2 (ja) * 2020-09-28 2026-03-04 カーデュリオン・ファーマシューティカルズ・インコーポレイテッド 縮合ヘテロアリール化合物およびＣａＭＫＩＩ阻害剤としてのその使用

Also Published As

Publication number Publication date
AU2021350015A1 (en) 2023-06-08
EP4216948A1 (en) 2023-08-02
JP7824282B2 (ja) 2026-03-04
CN116940354A (zh) 2023-10-24
IL301480A (en) 2023-05-01
US12528816B2 (en) 2026-01-20
US20220098207A1 (en) 2022-03-31
JP2023543038A (ja) 2023-10-12
CL2023000894A1 (es) 2023-09-15
PE20240148A1 (es) 2024-02-06
AU2021350015A9 (en) 2024-10-03
MX2023003610A (es) 2023-07-20
TW202229273A (zh) 2022-08-01
WO2022067082A1 (en) 2022-03-31
CO2023005189A2 (es) 2023-08-09
US20240182474A1 (en) 2024-06-06
KR20230107551A (ko) 2023-07-17
US11795172B2 (en) 2023-10-24
EP4216948A4 (en) 2024-08-28

Similar Documents

Publication Publication Date Title
CN110799190B (zh) 杂环化合物
KR102007056B1 (ko) 과증식성 질환 치료시 Bub1 키나제 저해제로 사용하기 위한 치환된 벤질인다졸
US11795172B2 (en) Substituted imidazo[1,2-b]pyridazines and [1,2,4]triazolo[4,3-b]pyridazines as CaMKII inhibitors
CA3155569A1 (en) Polyheterocyclic modulators of sting (stimulator of interferon genes)
KR20170040300A (ko) 2-(모르폴린-4-일)-l,7-나프티리딘
CN111918863B (zh) 杂环化合物
EP4188930A1 (en) Substituted heterocyclic compounds and therapeutic uses thereof
EP3856188B1 (en) Aminopyrimidine compound
EA052559B1 (ru) Конденсированные гетероарильные соединения и их применение в качестве ингибиторов camkii
NZ728416B2 (en) 2-(morpholin-4-yl)-1,7-naphthyridines

Legal Events

Date Code Title Description
P22 Classification modified

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED

Effective date: 20240916

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240918

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240918

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240918

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250704

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250704

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20250908

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20250908

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250908